This webinar featured a candid conversation with panelists from AMCP’s Market Insights Roundtable on Bridging the Gaps in Precision Oncology: Opportunities in Non-Small Cell Lung Cancer.
To understand the appropriate and cost-effective use of biomarker-driven treatment selection in NSCLC, AMCP convened an expert panel of managed care stakeholders.
The lack of implementation of predictive biomarkers in clinical practice results in a significant number of individuals with NSCLC not deriving benefits from targeted treatments. Payers have the potential to shape various aspects of the precision oncology pathway, such as addressing biomarker test ordering, utilizing test results to inform treatment decisions, implementing quality measurements, and understanding cost-effectiveness.
Despite clinical guidelines, biomarker testing is unevenly applied, leaving patients without access to targeted therapies. AMCP is engaging payers and providers to align coverage with best practices, expand real-world evidence, and reduce gaps in precision medicine adoption.
